Health insurers slide after CMS proposes just a 0.09% Medicare Advantage rate increase for 2027

U.S. health insurers’ shares fell sharply after the Centers for Medicare & Medicaid Services proposed a 0.09% increase in Medicare Advantage payment rates for 2027—well below what analysts and investors had expected. The proposal implies roughly $700 million in additional payments across the industry, a modest sum compared with prior years’ increases. ([investing.com](https://www.investing.com/news/stock-market-news/us-health-insurers-slump-after-2027-medicare-advantage-payments-proposal-disappoints-4466778?utm_source=openai))

The market reaction was immediate: premarket and early trading declines hit companies most exposed to Medicare Advantage, including UnitedHealth and Humana, with other firms like CVS and Elevance also pressured. Investors are trying to gauge whether insurers can absorb medical-cost trends without reducing benefits or pulling back in certain markets. ([ft.com](https://www.ft.com/content/cd12e11b-6bae-4238-8fc8-e93944578f6f?utm_source=openai))

Medicare Advantage is a large and growing segment of U.S. healthcare coverage for older adults and some people with disabilities. When payment updates come in below expectations, insurers may have to adjust plan design—such as narrowing networks, raising premiums, or cutting extra benefits—to protect margins. ([ft.com](https://www.ft.com/content/cd12e11b-6bae-4238-8fc8-e93944578f6f?utm_source=openai))

The CMS proposal also arrives amid heightened scrutiny of how Medicare Advantage coding and diagnoses affect federal payments. Changes to rules around risk adjustment and diagnosis reporting can shift revenue even if headline rate updates appear small, creating additional uncertainty for 2027 planning. ([investopedia.com](https://www.investopedia.com/here-is-why-health-insurance-stocks-are-sinking-tuesday-11893199?utm_source=openai))

The 0.09% figure is still a proposal, and CMS can revise the final payment notice later in the process. Until then, insurers, investors, and consumer advocates will focus on whether the administration prioritizes cost restraint, benefit stability for seniors, or some balance of the two in the final decision. ([ft.com](https://www.ft.com/content/cd12e11b-6bae-4238-8fc8-e93944578f6f?utm_source=openai))